Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $21,010.64 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 4,414 shares of SOPHiA GENETICS stock in a transaction on Monday, April 13th. The stock was sold at an average price of $4.76, for a total transaction of $21,010.64. Following the transaction, the insider directly owned 632,096 shares of the company’s stock, valued at $3,008,776.96. This represents a 0.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Zhenyu Xu also recently made the following trade(s):

• On Tuesday, April 14th, Zhenyu Xu sold 600 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.97, for a total transaction of $2,982.00.
• On Friday, April 10th, Zhenyu Xu sold 3,706 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.68, for a total transaction of $17,344.08.
• On Thursday, April 9th, Zhenyu Xu sold 1,936 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.74, for a total transaction of $9,176.64.
• On Wednesday, April 8th, Zhenyu Xu sold 2,800 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.84, for a total transaction of $13,552.00.
• On Tuesday, April 7th, Zhenyu Xu sold 2,400 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total transaction of $11,688.00.
• On Monday, April 6th, Zhenyu Xu sold 2,700 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total transaction of $13,095.00.
• On Thursday, March 19th, Zhenyu Xu sold 608 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.78, for a total transaction of $2,906.24.

SOPHiA GENETICS Price Performance

Shares of NASDAQ SOPH opened at $5.12 on Friday. SOPHiA GENETICS SA has a twelve month low of $2.58 and a twelve month high of $5.70. The firm has a fifty day simple moving average of $4.75 and a 200 day simple moving average of $4.72. The company has a market capitalization of $350.67 million, a PE ratio of -10.04 and a beta of 1.04. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.08). The company had revenue of $21.71 million during the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. On average, sell-side analysts forecast that SOPHiA GENETICS SA will post -0.96 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have commented on SOPH shares. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. Guggenheim raised their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, BTIG Research raised their price target on shares of SOPHiA GENETICS from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Wednesday. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $7.50.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Silverberg Bernstein Capital Management LLC grew its holdings in shares of SOPHiA GENETICS by 8.7% during the first quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after buying an additional 4,155 shares during the last quarter. Green Alpha Advisors LLC grew its holdings in shares of SOPHiA GENETICS by 10.8% during the fourth quarter. Green Alpha Advisors LLC now owns 45,660 shares of the company’s stock valued at $213,000 after buying an additional 4,444 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of SOPHiA GENETICS by 24.7% during the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock valued at $148,000 after buying an additional 6,205 shares during the last quarter. Savvy Advisors Inc. acquired a new position in shares of SOPHiA GENETICS during the third quarter valued at about $48,000. Finally, Squarepoint Ops LLC acquired a new position in shares of SOPHiA GENETICS during the third quarter valued at about $49,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

More SOPHiA GENETICS News

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Strategic commercial win — Mount Sinai Health System will adopt SOPHiA GENETICS’ AI-powered SOPHiA DDM™ platform to support precision cancer care and genomic testing at a major NCI-designated center, which could drive recurring software volume and credibility with large U.S. health systems. Mount Sinai collaboration
• Positive Sentiment: Sector tailwind — coverage highlighting Mount Sinai’s use of AI to speed genomic testing reinforces demand for AI-driven genomics platforms like SOPHiA DDM, supporting adoption and long-term revenue potential. Healthcare IT News
• Positive Sentiment: Analyst interest — several firms have set $7.00 targets and issued buy opinions (e.g., Guggenheim, BTIG), giving investors an upside reference versus current levels.
• Neutral Sentiment: Insider selling activity — multiple insiders (CEO Jurgi Camblong, President Ross Muken and others) disclosed sales totaling tens of thousands of shares in mid-April. All trades were executed under pre-arranged Rule 10b5-1 plans and many were described as tax-withholding sales tied to vested awards, which reduces immediate governance concern but increases float. SEC Form 4 (example)
• Negative Sentiment: Underlying profitability risks — the company reported a March-quarter EPS miss (reported ($0.28) vs. consensus ($0.20)), with negative net margins and a substantial negative ROE. Analysts still expect FY losses (consensus around -0.96 EPS), highlighting ongoing path-to-profitability concerns that can cap multiple expansion. Earnings & metrics

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.